Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02545348
Other study ID # StLucGsendo1
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date August 2015
Est. completion date September 2020

Study information

Verified date December 2019
Source Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Contact Mathieu LUYCKX
Phone 27649509
Email mathieu.luyckx@uclouvain.be
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is an obstervationnal study, to evaluate the good clinical practice of the use of the sentinel node biospy in early stage endometrial cancer. The collaborating centres with the OncoGynecology board of the King Albert II Institute of the Clinique Universitaire Saint-Luc will also particpate to the trial.

Sentinel node biospy is not yet validated for endometrial cancer, even if lots of leading team in the world published very good result and that the first prospectives trials are already published with also excellents results. The investigators decided then to include this practice in their institutional guideslines and also to registred the procedure.


Description:

All the sentinel node biopsy procedures for endometrial cancer will be record online via the REDCap tools, securized on a servor in Saint-Luc. Automatic email for the following of the patients and the post operative event will be send regularly for every patient to the physicians who include the patient. Efficacy of the technique, False negative and postive rate, modifications of the adjuvant treatement, long terme evolution and complication wil be evaluate.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date September 2020
Est. primary completion date August 2020
Accepts healthy volunteers No
Gender Female
Age group N/A and older
Eligibility Inclusion Criteria:

- Endometrial cancer early stage on the pre operative examinations

- Performance status that allow a surgery

- Surgery by laparoscopy or laparotomy

Exclusion Criteria:

- Patient already operated of the hysterectomy who need lymphatic restadification

- Stage IV disease

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Sentinel Lymph Node Biopsy
First, the detection of the sentinel node will be preformed at the beginning of the surgery. Differents detection methods are use and the efficacy of each will be recorded. Second, dissection and extraction of the sentinel node will be performed, to send it to the frozen section examination. Third, other lymph node could be removed if the surgeon evaluate that it is feasible and necessary. In this group, the false negative rate will be also evaluate.

Locations

Country Name City State
Belgium Clinique St Jean Brussel
Belgium Cliniques de l'Europe Brussel
Belgium Cliniques universitaires Saint-Luc Brussel
Belgium Hôpital d'Ixelles Brussel
Belgium Cliniques Saint-Anne - Saint Remi Bruxelles
Belgium GHDC Charleroi
Belgium Université de Liège Liège
Belgium CHU AMbroise Parée Mons Hainaut
Belgium Cliniques Saint-Pierre Ottignies Ottignies
Belgium CHWaPi Tournai

Sponsors (1)

Lead Sponsor Collaborator
Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary Detection rate of the sentinel lymph node biopsy regarding diffrent methods used by the investigators Each hemi pelvis is count as an unit for the detection rate, but also the detection per patient will be calculated. For a positive detection with the patient as an unit, the detection must be bilateral 5 years
Secondary Modification of the adjuvant treatement by the information bring by the sentinel node analysis An evaluation of the modification of the adjuvant treatement by the results of the node sentinel will be performed, in case of it was performed alone and then compared to the guides lines when no information on the nodal status is knowed. It will also be evaluated in cas where a complete lymphadenectomy was performed to evaluate the interest of the ultrastaging on the sentinel node. 5 years
Secondary Survival outcomes: Disease free survival (DFS) and Overvall survival (OS) will be evaluate. Influence of the use of the sentinel node only or in addition to the complete lymphadenectomy on the DFS and the OS by comparing with the litterature accorded DFS and OS will be evaluate. Type of reccurence will also be attentively observed, in order to ensure the safety of the sentinel node dissection only. If the technique is reliable, the rate of nodal reccurence after negative sentinel node should be low. 5 years
Secondary False positive rate of the frozen section analysis Each negative sentinel node at the frozen section analyse wil also undergo a second analysis after "calssical" preparation of the tissue and alos immunochemestry analysis 5 years
Secondary False negative rate of the sentinel node, after frosen section analyse and the complete analysis In the group of patient who underwent a complet lymphadenectomy, a false negative rate will be calculate, with a expected number really low. 5 years
Secondary Early and late complications of the procedure Per operative, early and late post operative complication related to the sentinel node procedure will be recorded in the REDCap file, and will be compared to the group of complete lymphadenectomy, with a special focus on lymphatics complications (lymphocyst, lymphoedema,...) 5 years
See also
  Status Clinical Trial Phase
Completed NCT00377520 - A Trial for Patients With Advanced/Recurrent Endometrial Cancer Phase 2
Recruiting NCT05179824 - Tempus Priority Study: A Pan-tumor Observational Study
Completed NCT02387645 - LUDEC Study - Pilot Study of the Lavage of the Uterine Cavity for the Diagnosis of Endometrial Carcinoma N/A
Recruiting NCT04438564 - Immunoassay and Regulation of Traditional Chinese Medicine on Cancer Patients N/A
Recruiting NCT05742711 - Efficacy of PENS of the Auricle as an Opioid Sparing Postoperative Analgesic Technique in Cancer Endometrium and Cancer Cervix Patients N/A
Suspended NCT06253494 - Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer Phase 1/Phase 2
Completed NCT04891146 - The Effect of Anesthesia on Systemic Inflammatory Immune Index in Major Abdominal Cancer Surgeries
Recruiting NCT05273099 - Molecular Biomarkers Predicting Early Development of Endometrial Carcinoma
Completed NCT05233059 - FitEx for Endometrial Cancer Survivors N/A
Recruiting NCT00726635 - The Assessment of Preoperative Psychological Intervention on Stress in Women With Gynecological Malignancies Phase 3
Completed NCT00859768 - The Effectiveness of the Screening Inventory of Psychosocial Problems (SIPP) in Cancer Patients N/A